|
|
|
| Inclusion of hepatitis A vaccine in Expanded Program on Immunization on hepatitis A incidence by interrupted time-series analysis |
| ZHANG Chao, LUO Xiao-fu, XU Qin-er
|
| Huzhou Center for Disease Control, Prevention, Huzhou, Zhejiang313000, China |
|
|
|
|
Abstract Objective To assess the impact of inclusion of hepatitis A vaccine in Expanded Program on Immunization（EPI）on hepatitis A incidence. Methods The data of patients with hepatitis A from 1998 to 2017 in Huzhou were collected through Huzhou Infectious Diseases Yearbook and China Disease Prevention and Control Information System. Interrupted time-series models were constructed using the year 2008 when hepatitis A vaccine was included in EPI as the intervention time point. The influence of hepatitis A vaccine into EPI on the hepatitis A incidence was evaluated by analyzing the changes in the level and slope of incidence before and after hepatitis A vaccine into EPI. Results Before the inclusion of hepatitis A vaccine in EPI,the average annual incidence rate of hepatitis A was 10.228/100 000 and the incidence of hepatitis A showed a significant descending trend with an annual decrement of 1.558/100 000. After the inclusion of hepatitis A vaccine in EPI,the average annual incidence rate of hepatitis A was 1.721/100 000 and the incidence of hepatitis A showed a significant descending trend with an annual decrement of 0.263/100 000. The average annual rate of decline in the hepatitis A incidence decreased by 1.295/100 000 after the inclusion of hepatitis A vaccine in EPI. Conclusion The incidence of hepatitis A significantly reduced after inclusion of hepatitis A vaccine in EPI,and the EPI strategy had a continuous effect on the decreasing trend of hepatitis A incidence.
|
|
Received: 27 November 2018
Revised: 25 January 2019
Published: 03 June 2019
|
|
|
|
|
|
[1] BRITO W I,ALVES-JUNIOR E R,OLIVEIRA R M,et al. Initial evaluation of universal immunization with a single dose against hepatitis A virus in Central Brazil[J]. Braz J Infect Dis,2018,22(3):166-170.
[2] 孙校金,王富珍,郑徽,等. 2004—2015年中国甲型病毒性肝炎流行病学特征分析[J]. 中华预防医学杂志,2017,51(12):1091-1096.
[3] 罗小福,金明娟,张超. 湖州市扩大免疫规划前后甲型病毒性肝炎流行特征分析[J]. 预防医学,2018,30(11):1120-1123.
[4] 邵华,王琦琦,胡跃华,等. 中断时间序列分析及其在公共卫生领域中的应用[J]. 中华流行病学杂志,2015,36(9):1015-1017.
[5] WAGNER A K,SOUMERAI S B,ZHANG F,et al.Segmented regression analysis of interrupted time series studies in medication use research[J]. J Clin Pharm Ther,2002,27(4):299-309.
[6] GONG S T,QIU X,SONG Y Y,et al.Effect of financially punished audit and feedback in a pediatric setting in China,within an antimicrobial stewardship program and as part of an international accreditation process[J]. Frontiers in Public Health,2016,20(4):1-10.
[7] ZHANG Y,DONOHUE J M,LAVE J R,et al.The effect of Medicare Part D on drug and medical spending[J]. N Engl J Med,2009,361(1):52-61.
[8] CACERES D C,ORTEGA-BARRIA E,NIETO J,et al.Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia:an interrupted time-series analysis[J]. Hum Vaccin Immunother,2018,14(5):1230-1233.
[9] 安晓慧,姚文清,方兴. 辽宁省含风疹成分疫苗纳入国家扩大免疫规划对风疹发病影响[J]. 中国公共卫生,2018,34(2):264-267.
[10] 宁桂军,吴丹,李军宏,等. 应用中断时间序列分析评价流行性乙型脑炎减毒活疫苗大规模预防接种的有效性[J]. 中国疫苗和免疫,2015,21(4):361-364.
[11] 金玫华,沈建勇,韩建康,等. 1995—2006年浙江省湖州市甲型病毒性肝炎流行特征分析[J]. 疾病监测,2008,23(9):542-544.
[12] 韩思阳. 甲型肝炎的流行病特征及甲肝疫苗的保护效果研究进展[J]. 生物化工,2018,4(5):140-143.
[13] 蓝岳云,姜宪尘. 免疫接种对衢州市甲型肝炎流行特征的影响[J]. 浙江预防医学,2015,27(12):1230-1232.
[14] YU P,HUANG L,LI H,et al.Epidemiological investigation of an outbreak of hepatitis A in rural China[J]. Int J Infect Dis,2015,33:191-195.
[15] 孙校金,王富珍,郑徽,等. 2004—2015年中国甲型病毒性肝炎流行病学特征分析[J]. 中华预防医学杂志,2017,51(12):1091-1096.
[16] 戴孟阳,王萍,孙百军,等. 甲型病毒性肝炎预警指标的探讨[J]. 中国预防医学杂志,2005,6(1):64-65.
[17] 段飞云. 大理地区2014年健康人群麻疹、白喉、甲型肝炎抗体水平及乙型肝炎表面抗体监测结果分析[J]. 中国卫生检验杂志,2017,27(1):120-122.
[18] 于石成,殷大鹏. 准实验设计方法在疫苗效果评价中的应用[J]. 首都公共卫生,2018,12(3):124-125. |
|
|
|
